API Gallery
The Omarigliptin market is projected to grow steadily between 2025 and 2035, registering a CAGR of 6.5% during the forecast period. This growth is primarily driven by the increasing prevalence of type 2 diabetes mellitus (T2DM) and the demand for long-acting DPP-4 inhibitors that improve patient adherence.
The Orphenadrine Citrate API market is projected to grow steadily between 2025 and 2035, registering a CAGR of 4.5% during the forecast period. Growth is primarily driven by increasing demand for muscle relaxants and anti-inflammatory therapies, alongside a rising geriatric population prone to musculoskeletal and neurological disorders requiring supportive care with APIs like Orphenadrine Citrate.
The Parecoxib Sodium market is projected to grow steadily between 2025 and 2035, registering a CAGR of 5.6% during the forecast period. This growth is primarily driven by the increasing prevalence of chronic pain and inflammation-related conditions and the expanding geriatric population, which is more susceptible to ailments requiring anti-inflammatory medications like Parecoxib Sodium.
The Pargeverine market is projected to grow steadily between 2025 and 2035, registering a CAGR of 5.6% during the forecast period. This growth is primarily driven by the increasing incidence of gastrointestinal and urological disorders, necessitating effective treatment options such as Pargeverine.
The Paricalcitol market is projected to grow at a CAGR of 6.2% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of chronic kidney disease (CKD) and secondary hyperparathyroidism, which are key therapeutic areas for Paricalcitol.
The Paritaprevir market is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of chronic hepatitis C infections and the demand for effective antiviral therapies.
The Eribulin API market is expected to grow steadily between 2025 and 2035, with an estimated CAGR of 6.7%. This growth is primarily driven by the increasing demand for novel microtubule-stabilizing agents in oncology, particularly for treating taxane-resistant cancers.
The Paroxetine Hydrochloride market is projected to grow steadily between 2025 and 2035, registering a CAGR of 4.5% during the forecast period. This growth is primarily driven by the increasing prevalence of depression and anxiety disorders, especially among the aging population.
The Pasireotide market is projected to grow steadily between 2025 and 2035, registering a CAGR of 2.6%, as inferred from the broader Pasireotide drugs segment. This moderate growth is driven by the increasing demand for rare endocrine disorder treatments, particularly acromegaly and Cushing’s disease.
The Patisiran market is projected to grow steadily between 2025 and 2035, registering a CAGR of 10.7% during the forecast period. This growth is primarily driven by the increasing prevalence of hereditary transthyretin-mediated amyloidosis (hATTR) and the demand for effective RNA interference (RNAi)-based therapies.
The Erlotinib API market is projected to experience steady growth between 2025 and 2035, with a CAGR of approximately 5.4%. This growth is primarily driven by the increasing demand for targeted therapies in oncology, particularly for the treatment of non-small cell lung cancer (NSCLC) and other EGFR-mutated cancers.
The Pazopanib Hydrochloride API market is projected to grow at a CAGR of 9.0% from 2025 to 2035, driven by the increasing prevalence of cancers such as renal cell carcinoma and soft tissue sarcoma.
The Pectin API market is projected to grow at a CAGR of 7.0% during the forecast period 2025–2035. This growth is primarily driven by rising demand for natural, plant-based ingredients across the food, pharmaceutical, and personal care industries.
The Pefloxacin market is projected to grow at a CAGR of 6.5% during the forecast period 2025–2035, driven by the increasing prevalence of bacterial infections and the rising demand for effective fluoroquinolone antibiotics.
The Pegcetacoplan market is projected to grow at a CAGR of 7.2% during the forecast period 2025–2035. This growth is primarily driven by the increasing prevalence of complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
